GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • American Society of Clinical Oncology (ASCO)  (9)
  • 1
    Online Resource
    Online Resource
    State Variation in Squamous Cell Carcinoma of the Anus Incidence and Mortality, and Association With HIV/AIDS and Smoking in the United States
    American Society of Clinical Oncology (ASCO) ; 2023
    In:  Journal of Clinical Oncology Vol. 41, No. 6 ( 2023-02-20), p. 1228-1238
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 41, No. 6 ( 2023-02-20), p. 1228-1238
    Abstract: Squamous cell carcinoma of the anus (SCCA) incidence and mortality rates are rising in the United States. Understanding state-level incidence and mortality patterns and associations with smoking and AIDS prevalence (key risk factors) could help unravel disparities and provide etiologic clues. METHODS Using the US Cancer Statistics and the National Center for Health Statistics data sets, we estimated state-level SCCA incidence and mortality rates. Rate ratios (RRs) were calculated to compare incidence and mortality in 2014-2018 versus 2001-2005. The correlations between SCCA incidence with current smoking (from the Behavioral Risk Factor Surveillance System) and AIDS (from the HIV Surveillance system) prevalence were evaluated using Spearman's rank correlation coefficient. RESULTS Nationally, SCCA incidence and mortality rates (per 100,000) increased among men (incidence, 2.29-3.36, mortality, 0.46-0.74) and women (incidence, 3.88-6.30, mortality, 0.65-1.02) age ≥ 50 years, but decreased among men age 〈 50 years and were stable among similar-aged women. In state-level analysis, a marked increase in incidence (≥ 1.5-fold for men and ≥ two-fold for women) and mortality (≥ two-fold) for persons age ≥ 50 years was largely concentrated in the Midwestern and Southeastern states. State-level SCCA incidence rates in recent years (2014-2018) among men were correlated ( r = 0.47, P 〈 .001) with state-level AIDS prevalence patterns. For women, a correlation was observed between state-level SCCA incidence rates and smoking prevalence ( r = 0.49, P 〈 .001). CONCLUSION During 2001-2005 to 2014-2018, SCCA incidence and mortality nearly doubled among men and women age ≥ 50 years living in Midwest and Southeast. State variation in AIDS and smoking patterns may explain variation in SCCA incidence. Improved and targeted prevention is needed to combat the rise in SCCA incidence and mitigate magnifying geographic disparities. [Media: see text]
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/JCO.22.01390
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2023
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    HIV Testing in Patients With Cancer at the Initiation of Therapy at a Large US Comprehensive Cancer Center
    American Society of Clinical Oncology (ASCO) ; 2015
    In:  Journal of Oncology Practice Vol. 11, No. 5 ( 2015-09), p. 384-390
    Details
    In: Journal of Oncology Practice, American Society of Clinical Oncology (ASCO), Vol. 11, No. 5 ( 2015-09), p. 384-390
    Abstract: To determine the rates of HIV testing and infection among patients with cancer at initiation of systemic cancer therapy. Methods: We conducted a retrospective cohort study of adults with cancer who registered at a comprehensive cancer center from January 2004 through April 2011 and received systemic cancer therapy. We determined rates of HIV-1/2 and/or Western blot testing and HIV positivity at initiation of systemic cancer therapy. Multivariable logistic regression was used to determine predictors of HIV testing. Results: Of 18,874 patients with cancer who received systemic cancer therapy during the study period, 3,514 (18.6%) were tested for HIV at initiation of cancer therapy. The prevalence of positive HIV test results was 1.2% (41 of 3,514), and the prevalence of newly diagnosed HIV was 0.3% (12 of 3,514). The HIV testing rate was lower in black than in white patients (13.7% v 19.2%), but the prevalence of positive test results was higher in black patients (4.5%) than in any other racial/ethnic group. Among patients with AIDS-defining cancers (eg, non-Hodgkin lymphoma and cervical cancer), predictors of HIV testing were history of non-Hodgkin lymphoma, younger age, and registration after 2006. Among patients with non–AIDS-defining cancers, predictors of HIV testing were younger age, registration after 2006, male sex, history of illicit drug use or sexually transmitted disease, having a hematologic malignancy, and black race. Conclusion: The prevalence of HIV infection among patients with cancer was 1.2%, higher than the 0.1% prevalence threshold above which national guidelines recommend routine opt-out testing; however, the overall HIV testing rate was low.
    Type of Medium: Online Resource
    ISSN: 1554-7477 , 1935-469X
    URL: Article
    DOI: 10.1200/JOP.2015.005116
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2015
    detail.hit.zdb_id: 3005549-0
    detail.hit.zdb_id: 2236338-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Building Capacity for Cancer Research in the Era of COVID-19: Implementation and Results From an International Virtual Clinical Research Training Program in Zambia
    American Society of Clinical Oncology (ASCO) ; 2022
    In:  JCO Global Oncology , No. 8 ( 2022-05)
    Details
    In: JCO Global Oncology, American Society of Clinical Oncology (ASCO), , No. 8 ( 2022-05)
    Abstract: The incidence of cancer in sub-Saharan Africa is increasing rapidly, yet cancer research in the region continues to lag. One contributing factor is limited exposure to clinical research among trainees. We describe implementation and results of a virtual clinical research training program for Zambian clinical oncology fellows developed jointly by the Cancer Diseases Hospital in Zambia and the MD Anderson Cancer Center to address this need. METHODS The clinical research training program consisted of 14 weekly virtual lectures, development of research questions by Zambian clinical oncology fellows, assignment of faculty and peer mentors, longitudinal mentorship of research protocols, and anonymous precourse and postcourse surveys. The paired t-test was used to analyze the change in academic self-efficacy scores. RESULTS Fourteen Zambian clinical oncology fellows participated. Senior fellows were paired with research mentors, leading to the development of eight research protocols. A total of 70 meetings and 126 hours of mentorship occurred with a median of seven meetings and 15 hours per pairing. The precourse and postcourse survey response rates were 86% and 79%, respectively. There were statistically significant increases in nine of 12 academic self-efficacy domains. The largest gains were in ability to independently perform research ( P 〈 .001) and research mentorship ( P = .02) with an average increase of 1.5 points on a five-point scale in both domains. CONCLUSION The Cancer Diseases Hospital MD Anderson Cancer Center clinical research training program for Zambian clinical oncology fellows led to increases in multiple academic self-efficacy domains among participants, formation of longitudinal mentorship groups with both faculty and peer mentors, and development of Zambian-led research protocols, demonstrating the feasibility of implementing a virtual model. This may be especially relevant because of shifting international collaboration paradigms after the COVID-19 pandemic.
    Type of Medium: Online Resource
    ISSN: 2687-8941
    URL: Article
    DOI: 10.1200/GO.21.00372
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2022
    detail.hit.zdb_id: 3018917-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Human Immunodeficiency Virus–Associated Squamous Cell Cancer of the Anus: Epidemiology and Outcomes in the Highly Active Antiretroviral Therapy Era
    American Society of Clinical Oncology (ASCO) ; 2008
    In:  Journal of Clinical Oncology Vol. 26, No. 3 ( 2008-01-20), p. 474-479
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 26, No. 3 ( 2008-01-20), p. 474-479
    Abstract: To evaluate and determine predictors of squamous cell carcinoma of the anus (SCCA) outcomes in the highly active antiretroviral therapy (HAART) era for HIV-positive and -negative individuals using large national Veterans Affairs (VA) Administration databases. Patients and Methods We used the VA administrative databases to perform a retrospective cohort study in 1,184 veterans diagnosed with SCCA between 1998 and 2004. We calculated HIV infection rates and used logistic regression to identify epidemiologic factors that were associated with HIV infection. Kaplan-Meier curves and Cox proportional hazards models were calculated to compare survival between HIV-positive and HIV-negative veterans. Results In our cohort, 175 patients (15%) were HIV positive. The median age of the HIV-negative and -positive patients was 63 and 49 years, respectively (P 〈 .001). Individuals with HIV were eight times more likely to be male (P = .01) and three times more likely to be African American (P 〈 .001). There were no differences between HIV-positive and HIV-negative individuals in the receipt of treatment. The 2-year observed survival rates were 77% and 75% among HIV-positive and HIV-negative individuals, respectively. In multivariate Cox analysis, significant predictors of survival were age, sex, metastasis at diagnosis, and comorbidity score. HIV infection did not affect survival. Conclusion A noteworthy proportion of individuals with SCCA in the VA system are HIV positive. HIV-associated SCCA seems mainly to be a disease among younger men. Survival of SCCA is equivalent between HIV-positive and HIV-negative individuals in the HAART era. Treatment should not be withheld or deintensified based on HIV status.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/JCO.2007.14.2810
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2008
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    Cancer incidence in U.S. adolescent and young adult (AYA) women stratified by race/ethnicity and region.
    American Society of Clinical Oncology (ASCO) ; 2022
    In:  Journal of Clinical Oncology Vol. 40, No. 16_suppl ( 2022-06-01), p. e18529-e18529
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, No. 16_suppl ( 2022-06-01), p. e18529-e18529
    Abstract: e18529 Background: Cancer incidence is higher in AYA women compared to men and is increasing. National trends by race/ethnicity and region for AYA women in the U.S. are needed to improve health care outcomes. Methods: Data about the top ten cancers 2001-2017, race/ethnicity, and 9 CDC divisions were extracted from US Cancer Statistics Public databases encompassing 99% of US population. Age-adjusted incidence and its annual percent change (APC) were generated using SEER*Stat and trends analyzed via joinpoint regression. All statistical tests were two sided. Results: The top ten cancers in AYA women were: breast (incidence of 26.7 per 100,000), thyroid (16.0), melanoma (11.5), cervical (8.8), colorectal (4.1), uterine (3.5), non-Hodgkin lymphoma (3.6), Hodgkin lymphoma (4.0), and leukemia (3.1). Hispanic women had the highest incidence of uterine and cervical cancer and leukemia. Incidence of breast and colorectal cancer and non-Hodgkin lymphoma was highest in NH Black. Thyroid and colorectal cancer, melanoma, and Hodgkin lymphoma incidences were highest in NH White. Incidence trends included: 1) rise in breast (APC 0.5%), uterine (2.9%) in 2001-2017, and colorectal cancer (2.2% 2001-2013; 6.7% 2013-2017); 2) thyroid cancer (APC 2.1-7.2%) 2001-2015; (-5.7%) 2015-2017; 3) melanoma (-1%) 2005-2017; 4) cervical cancer (-1.4%) 2001-2013; 5) non-Hodgkin lymphoma (-0.5%) in 2007-2017; 5) Hodgkin lymphoma (-0.9%) 2007-2017; 6) leukemia (2.4%) 2001-2012 (p 〈 0.05). Incidence trends by race/ethnicity included: 1) breast cancer rise in all groups except for NH Black; 2) thyroid cancer rise in all 2001-2015; fall in NH White 2015-2017; 3) melanoma fall in Hispanic and NH Other, rise in NH White 2001-2005); 4) cervical cancer decline in all, Hispanic 2001-2013; 5) colorectal and uterine cancer rise in all; 6) fall in non-Hodgkin lymphoma in NH Black 2005-2017; rise in NH Other; 8) fall in Hodgkin lymphoma in NH White; 7) ovarian cancer rise in Hispanic; 8) leukemia rise in all, NH black 2001-2015 (p 〈 0.05). Division incidence trends included: 1) breast cancer rise in New England and Middle Atlantic (APC 0.7%); 2) colorectal cancer rise in New England (3.5%) and Mountain (4%); 3) melanoma fall in West South Central (-1.1%); 4) cervix cancer fall in West South Central (-0.3%) and South Atlantic (-0.7%); 5) uterine cancer rise in East North Central (2.3%), South Atlantic (3.0%), and West South Central (4.3%); 6) non-Hodgkin lymphoma rise (0.54%) in Pacific; 7) leukemia rise in South Atlantic (2.4%) and West South Central (0.9%) (p 〈 0.05). Conclusions: Breast, colorectal, uterine cancer, and leukemia incidence rose in AYA women, while thyroid and cervical (2001-2013) cancer, melanoma and lymphoma incidence fell, with variation by race/ethnicity and division. Research to describe environmental, lifestyle, and healthcare/policy factors and correlate them with outcomes is an urgent unmet need to improve equity in cancer outcomes.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/JCO.2022.40.16_suppl.e18529
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2022
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    Feasibility and acceptability of implementing electronic patient reported outcomes (ePRO) collection in Zambia: Findings from a patient needs assessment.
    American Society of Clinical Oncology (ASCO) ; 2023
    In:  Journal of Clinical Oncology Vol. 41, No. 16_suppl ( 2023-06-01), p. 12115-12115
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 41, No. 16_suppl ( 2023-06-01), p. 12115-12115
    Abstract: 12115 Background: Studies in high-income countries have shown that systematic, remote and electronic collection of patient-reported outcomes (ePROs) during chemotherapy, with provider intervention if symptoms worsen, is associated with fewer symptoms, better quality of life (QOL), and improved survival. It is unknown whether similar ePRO interventions, often using electronic medical record patient portals or mobile devices, can improve outcomes for cancer patients in low- and middle-income countries (LMICs). In sub-Saharan Africa (SSA), cervical cancer (CC) is the second most common cancer and most common cause of cancer deaths in women. As most patients are diagnosed with locally advanced disease, chemoradiotherapy is standard care; many have severe comorbidities such as HIV. Due to patients’ increased risk for high symptom burden, remote monitoring of ePROs during CC treatment may improve outcomes. We evaluated the feasibility and acceptability of ePRO collection in CC patients from SSA. Methods: Patients were recruited from a prospective cohort study of women with newly diagnosed CC at the Cancer Diseases Hospital in Lusaka, Zambia from June 2022 through January 2023. Patients completed an in-person interview regarding mobile technology usage comprising questions adapted from the 2019 Pew Report on Mobile Connectivity in Emerging Economies and the 2019 Global System for Mobile Communication Association Mobile Gender Gap Report. Questions were translated into 4 primary Zambian languages (Tonga, Nyanga, Lozi and Bemba). Results: Respondents’ (n = 100) mean age was 49.6 years (range, 29-75, SD 9.2), 55% were diagnosed with stage III-IV disease and 59% were HIV+. Most (70%) completed only primary school or no school, 29% reported not being able to read at all and 29% could read only parts of a sentence. Most personally owned a mobile phone (90%) and 8% reported using a phone that belonged to another person. Most used phones to make or receive calls (98%), for banking/mobile money (92%), and text messaging (67%). Of the 26% who owned a smartphone, only half connected to the internet by phone more than once weekly. Nearly all indicated willingness to use a phone to self-report CC-related symptoms if compensated for costs (98%), with 97% preferring to do so via a phone call and fewer via text message (43%) or mobile app (17%). Most (71%) were able to charge phones at home using electricity or solar power and 18% traveled more than 30 minutes to charge phones. Conclusions: Nearly all patients owned or had access to mobile phones and expressed willingness to self-report CC symptoms via phone. Findings support the feasibility and acceptability of ePRO collection and provide contextual data to guide implementation in LMICs, including consideration of telecommunications infrastructure and literacy, low internet use, and ePRO reporting preferences (i.e., calls vs text).
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/JCO.2023.41.16_suppl.12115
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2023
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 7
    Online Resource
    Online Resource
    AMC 095 (AIDS Malignancy Consortium): A phase I study of ipilimumab (IPI) and nivolumab (NIVO) in advanced HIV associated solid tumors (ST) with expansion cohorts in HIV associated solid tumors and classical Hodgkin lymphoma (cHL).
    American Society of Clinical Oncology (ASCO) ; 2018
    In:  Journal of Clinical Oncology Vol. 36, No. 15_suppl ( 2018-05-20), p. TPS2597-TPS2597
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 36, No. 15_suppl ( 2018-05-20), p. TPS2597-TPS2597
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/JCO.2018.36.15_suppl.TPS2597
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2018
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 8
    Online Resource
    Online Resource
    Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium
    American Society of Clinical Oncology (ASCO) ; 2023
    In:  Journal of Clinical Oncology Vol. 41, No. 21 ( 2023-07-20), p. 3712-3723
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 41, No. 21 ( 2023-07-20), p. 3712-3723
    Abstract: CATCH-IT consortium study by @talalzarif1 @aminnassarMD @adlib_elio @thenasheffect et al demonstrates #ICI safety and activity across cancer types in people with #HIV. Also, similar outcomes in a matched cohort of people with and without HIV with metNSCL.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/JCO.22.02459
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2023
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 9
    Online Resource
    Online Resource
    Clinical Trials for Treatment and Prevention of HIV-Associated Malignancies in Sub-Saharan Africa: Building Capacity and Overcoming Barriers
    American Society of Clinical Oncology (ASCO) ; 2020
    In:  JCO Global Oncology , No. 6 ( 2020-11), p. 1134-1146
    Details
    In: JCO Global Oncology, American Society of Clinical Oncology (ASCO), , No. 6 ( 2020-11), p. 1134-1146
    Abstract: The aim of this study was to review the current status of clinical trials for HIV-associated malignancies in people living with HIV in sub-Saharan Africa (SSA) and efforts made by the AIDS Malignancy Consortium (AMC) to build capacity in SSA for HIV malignancy research. METHODS All malignancy-related clinical trials in 49 SSA countries on ClinicalTrials.gov were reviewed and evaluated for inclusion and exclusion criteria pertaining to HIV status. Additional studies by AMC in SSA were compiled from Web-based resources, and narrative summaries were prepared to highlight AMC capacity building and training initiatives. RESULTS Of 96 cancer trials identified in SSA, only 11 focused specifically on people living with HIV, including studies in Kaposi sarcoma, cervical dysplasia and cancer, non-Hodgkin lymphoma, and ocular surface squamous neoplasia. Recognizing the increasing cancer burden in the region, AMC expanded its clinical trial activities to SSA in 2010, with 4 trials completed to date and 6 others in progress or development, and has made ongoing investments in developing research infrastructure in the region. CONCLUSION As the HIV-associated malignancy burden in SSA evolves, research into this domain has been limited. AMC, the only global HIV malignancy-focused research consortium, not only conducts vital HIV-associated malignancies research in SSA, but also develops pathology, personnel, and community-based infrastructure to meet these challenges in SSA. Nonetheless, there is an ongoing need to build on these efforts to improve HIV-associated malignancies outcomes in SSA.
    Type of Medium: Online Resource
    ISSN: 2687-8941
    URL: Article
    DOI: 10.1200/GO.20.00153
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2020
    detail.hit.zdb_id: 3018917-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...